These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37080262)

  • 41. Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
    Peters MG; Yuen MF; Terrault N; Fry J; Lampertico P; Gane E; Hwang C; Stamm LM; Leus M; Maini MK; Mendez P; Lonjon-Domanec I; Berg T; Wang S; Mishra P; Donaldson E; Buchholz S; Miller V; Lenz O
    Clin Infect Dis; 2024 Apr; 78(4):983-990. PubMed ID: 37633256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure.
    Tsounis EP; Tourkochristou E; Mouzaki A; Triantos C
    World J Gastroenterol; 2021 Jun; 27(21):2727-2757. PubMed ID: 34135551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical cure of hepatitis B: consensus and controversy].
    Hou JL; Wei L; Wang GQ; Jia JD; Duan ZP; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):636-639. PubMed ID: 32911898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials.
    Hui RW; Mak LY; Seto WK; Yuen MF
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):127-140. PubMed ID: 35511483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
    Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
    Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue.
    Ramji A; Doucette K; Cooper C; Minuk GY; Ma M; Wong A; Wong D; Tam E; Conway B; Truong D; Wong P; Barrett L; Ko HH; Haylock-Jacobs S; Patel N; Kaplan GG; Fung S; Coffin CS
    World J Gastroenterol; 2022 Aug; 28(31):4390-4398. PubMed ID: 36159017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy.
    Li MH; Yi W; Zhang L; Lu Y; Lu HH; Shen G; Wu SL; Hao HX; Gao YJ; Chang M; Liu RY; Hu LP; Cao WH; Chen QQ; Li JN; Wan G; Xie Y
    J Viral Hepat; 2019 Jul; 26 Suppl 1():32-41. PubMed ID: 31380582
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues.
    Chen CH; Chiu YC; Lu SN; Lee CM; Wang JH; Hu TH; Hung CH
    World J Gastroenterol; 2014 Jun; 20(24):7686-95. PubMed ID: 24976706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy.
    Wang ML; Chen EQ; Tao CM; Zhou TY; Liao J; Zhang DM; Wang J; Tang H
    Scand J Gastroenterol; 2017 Dec; 52(12):1420-1426. PubMed ID: 28880694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Past, present, and future of long-term treatment for hepatitis B virus.
    Broquetas T; Carrión JA
    World J Gastroenterol; 2023 Jul; 29(25):3964-3983. PubMed ID: 37476586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel targets for hepatitis B virus therapy.
    Testoni B; Durantel D; Zoulim F
    Liver Int; 2017 Jan; 37 Suppl 1():33-39. PubMed ID: 28052622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How to achieve immune control in chronic hepatitis B?
    van Campenhout MJ; Janssen HL
    Hepatol Int; 2015 Jan; 9(1):9-16. PubMed ID: 25788374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine.
    Colombatto P; Coco B; Bonino F; Brunetto MR
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hepatitis B virus infection: control or cure?].
    Bourlière M; Oules V; Adhoute X
    Rev Prat; 2018 Mar; 68(3):276-282. PubMed ID: 30869285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of HBV surface antigen isoforms in the natural history and treatment of HBV infection.
    Rodgers MA; Shah PA; Anderson M; Vallari AS; Gersch J; Mbanya D; Sauleda Oliveras S; Choudhry S; Leary TP; Kuhns MC; Dawson GJ; Cloherty GA; Lau DTY
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 37026760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.